Autologous Dendritic Cell Vaccination in Mesothelioma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 3, 2017

Primary Completion Date

March 9, 2025

Study Completion Date

March 9, 2025

Conditions
Malignant Pleural Mesothelioma
Interventions
BIOLOGICAL

dendritic cell vaccination plus chemotherapy

"A. Chemoimmunotherapy:~1. four 3-weekly cycles of platinum/pemetrexed; on day 1 of each cycle, pemetrexed 500 mg/m2 should be administered as intravenous (IV) infusion over 10 minutes followed 30 minutes later by cisplatin 75 mg/m2 as IV over approximately 2 hours.~2. four intradermal vaccinations with 8-10 x 10e6 autologous WT1 mRNA-loaded DCs; at day 14+/- 3 days after the start of each chemotherapy cycle.~B. Surgery: pleurectomy/decortication; in case of resectable disease, 4-6 weeks after start of the last chemotherapy cycle."

Trial Locations (3)

2650

Antwerp University Hospital, Edegem

9000

AZ Middelares, Ghent

9100

AZ Nikolaas, Sint-Niklaas

All Listed Sponsors
collaborator

Kom Op Tegen Kanker

OTHER

collaborator

Stichting tegen Kanker

OTHER

lead

University Hospital, Antwerp

OTHER

NCT02649829 - Autologous Dendritic Cell Vaccination in Mesothelioma | Biotech Hunter | Biotech Hunter